TOP > 外国特許検索 > DEVICE FOR PROPHYLAXIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

DEVICE FOR PROPHYLAXIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

外国特許コード F120006398
整理番号 10011
掲載日 2012年4月3日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2011JP078506
国際公開番号 WO 2012077774
国際出願日 平成23年12月9日(2011.12.9)
国際公開日 平成24年6月14日(2012.6.14)
優先権データ
  • 特願2010-276407 (2010.12.10) JP
発明の名称 (英語) DEVICE FOR PROPHYLAXIS AND TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
発明の概要(英語) [Problem] The purpose of the present invention is to provide a device for the prophylaxis and treatment of systemic lupus erythematosus, a method for use as a biomarker of systemic lupus erythematosus, and a method for determining systemic lupus erythematosus.
[Solution] The prophylaxis/treatment of systemic lupus erythematosus is characterized by reducing the concentration of Hsp90 in the blood, the serum, or the blood plasma of a subject by using a substance capable of removing Hsp90. The method for use as a biomarker of systemic lupus erythematosus is characterized by using Hsp90 in the blood, the serum, or the blood plasma of a subject as a biomarker. The method for determining systemic lupus erythematosus is characterized by comparing and evaluating the concentration of Hsp90 in the blood, the serum, or the blood plasma of a subject with/against that of a normal control.
従来技術、競合技術の概要(英語) BACKGROUND ART
Systemic lupus erythematosus (systemic lupus erythematosus; SLE) (hereinafter, simply referred to as' SLE ' also displayed.) Is, anti-nuclear antibody or anti-DNA antibody or the immune complex in various organs, tissue induced by the deposition of inflammatory reactions may occur in a systemic autoimmune disease. There are a variety of clinical symptoms, the heat generation, anemia, thrombocytopenia, facial butterfly erythema, the erythema-like rash, the multi-joint pain, arthritis and serosa, kidney condition, diarrhea, cardiovascular symptoms are seen.
SLE is not yet clear the cause of the details of, in addition to genetic factors, ultraviolet, viral infection, trauma, surgery, pregnancy, childbirth, and environmental factors such as drug treatments involving thought to develop. In addition, in the SLE, interferon α peak value in the serum of exacerbations of the disease state is considered to be one of the factors.
Diagnosis of SLE, butterfly erythema cheek 1, 2 occurs at the site of the other distinctive rash, sensitivity to light 3, 4 in the mouth ulcers, arthritis 5, 6 lung, heart, other organs in the vicinity of the accumulated water (serosa flame), renal dysfunction 7, 8 decrease in white cell count, decrease in the number of red blood cells with a hemolytic anemia, decreased platelet count, 9 such as the brain and neuronal dysfunction, anti-nuclear antibody reaction in the blood test 10 positive, 11 stranded DNA antibody blood test for anti-2 positive, 11 of items, corresponding to the two or more of the 4 is performed by it can be confirmed. However, these diagnostic items include, severe symptoms of the heart and therefore, a more powerful early diagnosis in order to also possible, new diagnostic items have been required.
In addition, the treatment of SLE, mild symptoms in the case of non-steroidal anti-inflammatory agents such as aspirin is used, in the case of severe symptoms, at the present, such as prednisolone and adrenal cortical steroid drug is mainly used. Corticosteroid agents, anti-inflammatory effect and because of the immune, inflammation and improve an organ lesions in SLE and, in the production of autoantibodies or autoreactive lymphocytes by inhibiting the function of, a treatment for SLE are believed to be effective. However, a corticosteroid agent, which also reduces the function of protection against infection of the human on the other, high blood pressure, heart failure, diabetes, peptic ulcer disease, renal failure, osteoporosis and the like are deteriorated in some cases, their use requires sufficient attention should be paid. In addition, a corticosteroid drug over a long period, by intravenous injection or oral use, high blood pressure, increase in blood glucose level, cataracts, osteoporosis, hemorrhagic side effects such as the stomach is also a problem that occurs. Therefore, a corticosteroid agent other than the development of therapeutic agents is performed in SLE. For example, to Patent Document 1, a family of enzymes the inhibitory capacity of PDE4, 9 and 2 of adenine and optionally at the position being derived from the N (6) - substituted adenine compound, can be used in the treatment of SLE has been disclosed. However, such compounds, or a combination of drugs and corticosteroids assumed. In such a situation, fewer side-effects, a new method of treatment of SLE has been demanded.
In addition, heat shock protein (HSP) is, by heat shock protein to increase expression, radiation other than heat, may also react to the stress such as malnutrition known to increase. As a function of the heat shock protein, and the various proteins in the cell form a complex, thereby stabilizing the protein to function properly and function as molecular chaperones, in particular heat shock protein (Hsp90) is of the 90 client proteins such as protein kinase or a steroid hormone receptors which play an important role in cell proliferation and differentiation of signal transduction molecules are known to often. In addition, the heat shock protein, forming a complex with the peptide and, when exposed to stress from infected cells or tumor cells is released outside the cells, and contributes to the immune response has also been known.
In addition, the non-patent document 1, interferon α interferon γ and Hsp90 can be activated and, by comprising the inhibitor of Hsp90, and interferons α antiviral effect of interferon γ suppresses been described. In addition, in Patent Document 2, Tumor Necrosis Factor α (Tumor Necrosis Factor Hsp90 α: TNF α) and interleukin 6 (IL-6) to activate and is described, in its claim 21, systemic lupus erythematosus (SLE) Hsp90 inhibitors such as by administering to the patient, a method of reducing TNF α and IL-6 has been described. In addition, by the present inventors is the non-patent document 2, a complex with its own DNA Hsp90 (Hsp90 - self-DNA complex) is formed, and to suppress the decomposition of the self-DNA, and, as human DNA-plasma cells and efficiently incorporated into the dendritic cells, dendritic cells may be transformed with DNA in which the self-cell-like can be localized in the endosome initial, dendritic cell-like human traits can facilitate the production of interferon-α has been suggested. Further, in Non-Patent Document 3, in the peripheral blood mononuclear cells in patients with SLE, and increased expression of Hsp90 that has been described. However, Hsp90 is not a secreted protein, its concentration in the serum of SLE patients is significantly increased not contemplated that, in addition, also not known.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • SAPPORO MEDICAL UNIVERSITY
  • 発明者(英語)
  • TAMURA Yasuaki
  • SATOH Noriyuki
  • TORIGOE Toshihiko
  • SAITOH Keita
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PE PG PH PL PT QA RO RS RU RW SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ MD RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

PAGE TOP

close
close
close
close
close
close